ライフサイエンスコーパス: multidrug transporter

1 ropose to rename yegMNOB as mdtABCD (mdt for multidrug transporter).

2 nce of NorA functioning as a self-sufficient multidrug transporter.

3 nhibitors in the body may be affected by the multidrug transporter.

4 lysis to drug pumping by P-glycoprotein, the multidrug transporter.

5 ay be involved in the phosphorylation of the multidrug transporter.

6 lyspecific drug binding pocket in this yeast multidrug transporter.

7 iosynthesis enzymes or altered expression of multidrug transporters.

8 hodamine 123 (Rho-123), another substrate of multidrug transporters.

9 can have broad specificity, as in so-called multidrug transporters.

10 of its mammalian counterparts and bacterial multidrug transporters.

11 on, thus expanding the substrate spectrum of multidrug transporters.

12 velopment of novel specificities in existing multidrug transporters.

13 the exceptional promiscuous capabilities of multidrug transporters.

14 and anionic lipids on the activity of these multidrug transporters.

15 ta lmrA Delta lmrCD lacking major endogenous multidrug transporters.

16 ral operons encoding confirmed and predicted multidrug transporters.

17 nts, has been compromised by the presence of multidrug transporters.

18 op are divergent from those of the bacterial multidrug transporters.

19 ence that caspofungin is not a substrate for multidrug transporters.

20 e receptors, along with the participation of multidrug transporters, 5-lipoxygenase, and G protein-co

21 scent of those of other ATP-binding cassette multidrug transporters: a relatively high Km for ATP (1.

22 ane in hepatocytes, highly homologous to the multidrug transporter ABCB1.

23 tral regulator of xenobiotic defense via the multidrug transporter ABCB1/MDR1 p-gp.

24 ABCB4 shares high sequence identity with the multidrug transporter, ABCB1, its N-terminal domain is p

25 2-driven migration through activation of the multidrug transporters, Abcb1 and Abcc1, and through 5-l

26 Here we report that the major multidrug transporter ABCG2 (BCRP/MXR) is directly and s

27 for resistance-nodulation-cell division-type multidrug transporters, abolished the BaeR-induced incre

28 n Escherichia coli, there are at least three multidrug transporters (AcrAB/TolC, MdfA, and NorE) that

29 onally important switch loop of the trimeric multidrug transporter AcrB separates the access and deep

30 MtaN (Multidrug Transporter Activation, N terminus) is a const

31 ity for MDR1 substrates, but it did not have multidrug transporter activity.

32 sult, is important for the distribution of a multidrug transporter and hence sensitivity to antifunga

33 us thermophilus; it is homologous to various multidrug transporters and contains one degenerate site

34 nding other questions about the evolution of multidrug transporters and their natural physiological r

35 esistance genes in the whiB7 regulon, tap (a multidrug transporter) and erm(37) (a ribosomal methyltr

36 not meiotic mapping could exclude the Abcc1 multidrug transporter, and this was confirmed further by

37 Multidrug transporters are integral membrane proteins th

38 istance in this tumor type and defining this multidrug transporter as a target for pharmacologic supp

39 gemcitabine effectiveness by down-regulating multidrug transporters as well by converting gemcitabine

40 a 4-fold stimulation of the P-glycoprotein (multidrug transporter) ATPase.

41 yaluronan receptor CD44 forms complexes with multidrug transporters, BCRP (ABCG2) and P-glycoprotein

42 Multidrug transporters belonging to the multidrug and to

43 n of the gene encoding the Bacillus subtilis multidrug transporter Blt suggests a specific function f

44 mbrane proline P347 of the Bacillus subtilis multidrug transporter Bmr significantly increases the to

45 The Bacillus subtilis multidrug transporter Bmr, a member of the major facilit

46 pon drug binding activates expression of the multidrug transporter Bmr.

47 The multidrug transporters breast cancer resistance protein

48 The multidrug transporter, breast cancer resistance protein,

49 ed to homology model human and microbial ABC multidrug transporters by computational methods, the abi

50 Individual multidrug transporters can be extremely versatile, often

51 The similarly broad substrate specificity of multidrug transporters can be governed by the same struc

52 mical-induced accumulation of several binary multidrug transporter complexes that largely paralleled

53 ional (3D) structure of the Escherichia coli multidrug transporter EmrE by electron cryomicroscopy of

54 olled, efficient reconstitution of the small multidrug transporter EmrE in a simple model membrane an

55 We have refolded the small multidrug transporter EmrE in vitro from a denatured sta

56 The bacterial multidrug transporter EmrE is a dual-topology membrane p

57 drug-proton exchange in the Escherichia coli multidrug transporter, EmrE.

58 P-glycoprotein is a multidrug transporter encoded by the MDR1 gene.

59 Furthermore, the number of multidrug transporters encoded in each genome is so larg

60 glycoprotein (Pgp), the ATP-binding cassette multidrug transporter, exhibits a drug (substrate)-stimu

61 eptor kinases or anti-apoptotic pathways and multidrug transporter expression or function.

62 The small multidrug transporter from Escherichia coli, EmrE, coupl

63 EmrE, a multidrug transporter from Escherichia coli, functions a

64 LmrP is a major facilitator superfamily multidrug transporter from Lactococcus lactis that media

65 EmrD is a multidrug transporter from the Major Facilitator Superfa

66 Similar to the multidrug transporters from eukaryotic cells and Gram-po

67 Many multidrug transporters from gram-negative bacteria belon

68 ein QacR represses transcription of the qacA multidrug transporter gene and is induced by multiple st

69 ein QacR represses transcription of the qacA multidrug transporter gene and is induced by structurall

70 BmrR activates transcription of the multidrug transporter gene, bmr, in response to cellular

71 GF-R) activation and the expression of ABCC1 multidrug transporter gene, thus contributing to tumor c

72 zole resistance is upregulated expression of multidrug transporter genes CDR1 and PDH1.

73 ns specificity for other known substrates of multidrug transporters has never been tested.

74 RND-type multidrug transporters have an extremely broad substrate

75 ditionally, advances in the understanding of multidrug transporters have been made through biochemica

76 Multidrug transporters have long puzzled researchers bec

77 EmrE is a small multidrug transporter in Escherichia coli that extrudes

78 reveal the natural function of the system of multidrug transporters in B. subtilis and serve as a par

79 ial challenges alter expression of placental multidrug transporters in rodents.

80 known regulator of the expression of several multidrug transporters in Staphylococcus aureus.

81 -dependent transport kinetics of MexAB-OprM (multidrug transporter) in Pseudomonas aeruginosa in real

82 ast to the behavior observed with some other multidrug transporters, including OCT2, the results sugg

83 se inhibition of transport activity of other multidrug transporters, including the organic cation tra

84 lastine, and rifampicin) of the well studied multidrug transporters inhibit DrrAB-mediated Dox transp

85 mission in mammalian organisms and bacterial multidrug transporters involved in antibiotic resistance

86 The yeast Pdr5 multidrug transporter is an important member of the ATP-

87 active efflux of cytotoxic drugs mediated by multidrug transporters is the basis of multidrug resista

88 as suggested that P-glycoprotein (P-gp), the multidrug transporter, is phosphorylated by protein kina

89 The major facilitator superfamily multidrug transporter LmrP from Lactococcus lactis catal

90 The paradigm multidrug transporter, mammalian P-glycoprotein, was ide

91 The Escherichia coli multidrug transporter MdfA exchanges a single proton wit

92 can be restored either by expression of the multidrug transporter MdfA from a multicopy plasmid or b

93 drug conjugates (ADC) are substrates for the multidrug transporter MDR1.

94 he close functional relationship between the multidrug transporter (MDR1) and phosphatidylcholine fli

95 at-3-specific transcriptional activation and multidrug transporter, MDR1 (P-glycoprotein) gene expres

96 ositide 3-kinase stimulate expression of the multidrug transporter, MDR1 (P-glycoprotein), in an inte

97 al and molecular evidence for acquisition of multidrug transporter-mediated efflux activity as a cons

98 xpenditure to substrate translocation in the multidrug transporter MsbA.

99 structural and biochemical data for several multidrug transporters now provide mechanistic insights

100 issect genetically the regulation of NorA, a multidrug transporter of Staphylococcus aureus, we analy

101 EmrE is a bacterial multidrug transporter of the small multidrug resistance

102 The expression of two highly similar multidrug transporters of Bacillus subtilis, Bmr and Blt

103 ly been seen in ion channels but is known in multidrug transporters of the SMR family, and is suggest

104 mice, were used to study the effects of the multidrug transporters on the pharmacokinetics of PhIP a

105 quently attributed to enhanced expression of multidrug transporters or to the action of receptor kina

106 Co-expression of the human multidrug transporter P-glycoprotein (of which both drug

107 obe the substrate binding sites of the human multidrug transporter P-glycoprotein (P-gp).

108 The multidrug transporter P-glycoprotein (P-gp, ABCB1) is an

109 The multidrug transporter P-glycoprotein (Pgp) is an ATPase

110 everse drug resistance mediated by the human multidrug transporter P-glycoprotein (Pgp) with a stereo

111 The reactivity of the ATP-dependent multidrug transporter P-glycoprotein (Pgp) with the conf

112 SA), which is a competitive inhibitor of the multidrug transporter p-glycoprotein (pgp).

113 ), the rat parallel to human CYP3A4, and the multidrug transporter P-glycoprotein (Pgp).

114 The human multidrug transporter P-glycoprotein (Pgp, ABCB1) contri

115 analogue PSC 833, a potent inhibitor of the multidrug transporter P-glycoprotein.

116 The MDR1 multidrug transporter P-gp (P-glycoprotein) is an efflux

117 otease inhibitors are recognized by the MDR1 multidrug transporter (P-glycoprotein, or P-gp), thereby

118 st phase (CML-BP) cells commonly express the multidrug transporter, P-glycoprotein (Pgp).

119 The multidrug transporter, P-glycoprotein, expressed at the

120 as been determined for the NBDs of the human multidrug transporter, P-glycoprotein.

121 haracterized a mutation (S558Y) in the yeast multidrug transporter Pdr5 that uncouples ATP hydrolysis

122 he putative drug-binding pocket of the yeast multidrug transporter Pdr5.

123 The yeast (Saccharomyces cerevisiae) multidrug transporter Pdr5p effluxes a broad range of su

124 The yeast ABC (ATP-binding cassette protein) multidrug transporter Pdr5p transports a broad spectrum

125 Multidrug transporters pump structurally dissimilar toxi

126 As opposed to the majority of inhibitors of multidrug transporters, Reversan was not toxic by itself

127 rlR and brlR expression are not activated by multidrug transporter substrates.

128 caused by overexpression or overactivity of multidrug transporters, such as P-glycoprotein (P-gp), a

129 Low-resolution structural studies of multidrug transporters suggest that they possess similar

130 tease inhibitors are substrates of the human multidrug transporter, suggesting that cells in patients

131 EmrE, a member of the small multidrug transporters superfamily, extrudes positively

132 ein (BCRP; ABCG2) is an ATP-dependent efflux multidrug transporter that belongs to the G family of ha

133 P-glycoprotein (P-gp) is a multidrug transporter that uses energy from ATP hydrolys

134 EmrE is a multidrug transporter that utilises the proton gradient

135 of multidrug resistance (MDR) is a group of multidrug transporters that are often regulated at the t

136 VMAT2 is a member of the DHA12 family of multidrug transporters that belongs to the major facilit

137 VMAT2 is a member of the DHA12 family of multidrug transporters that belongs to the major facilit

138 EmrE belongs to a family of eubacterial multidrug transporters that confer resistance to a wide

139 Bacteria express several multidrug transporters that recognize structurally dissi

140 The efflux of chemically diverse drugs by multidrug transporters that span the membrane is one mec

141 In the well studied P-glycoprotein multidrug transporter, the two appear to be functionally

142 Unlike the multidrug transporters, the cytosolic multidrug-binding

143 aspects of the transformation of a bacterial multidrug transporter to a mammalian neurotransporter an

144 Secondary multidrug transporters use ion concentration gradients t

145 , in response, activates the expression of a multidrug transporter which expels them out of the cell.

146 (VMAT2) has sequence homology with bacterial multidrug transporters which in turn share homology with

147 ent manner the photoaffinity labeling of the multidrug transporter with 125I-iodoarylazidoprazosin an